0001140361-23-034994.txt : 20230718
0001140361-23-034994.hdr.sgml : 20230718
20230718161511
ACCESSION NUMBER: 0001140361-23-034994
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230714
FILED AS OF DATE: 20230718
DATE AS OF CHANGE: 20230718
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WAGNER RICHARD W
CENTRAL INDEX KEY: 0001277280
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11460
FILM NUMBER: 231094416
MAIL ADDRESS:
STREET 1: C/O PRAECIS PHARMACEUTICALS INC
STREET 2: 830 WINTER ST
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Eterna Therapeutics Inc.
CENTRAL INDEX KEY: 0000748592
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 311103425
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1035 CAMBRIDGE STREET
STREET 2: SUITE 18A
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: (212) 582-1199
MAIL ADDRESS:
STREET 1: 10531 4S COMMONS DRIVE
STREET 2: SUITE 166-550
CITY: SAN DIEGO
STATE: CA
ZIP: 92127
FORMER COMPANY:
FORMER CONFORMED NAME: Brooklyn ImmunoTherapeutics, Inc.
DATE OF NAME CHANGE: 20210325
FORMER COMPANY:
FORMER CONFORMED NAME: NTN BUZZTIME INC
DATE OF NAME CHANGE: 20051230
FORMER COMPANY:
FORMER CONFORMED NAME: NTN COMMUNICATIONS INC
DATE OF NAME CHANGE: 19920703
4
1
form4.xml
X0508
4
2023-07-14
0000748592
Eterna Therapeutics Inc.
ERNA
0001277280
WAGNER RICHARD W
C/O ETERNA THERAPEUTICS INC.
1035 CAMBRIDGE STREET, SUITE 18A
CAMBRIDGE
MA
02141
true
false
6.0% Senior Convertible Promissory Notes due 2028
2.86
2023-07-13
4
P
0
120000
120000
A
2023-07-14
2028-07-14
Common Stock
41958
120000
D
Warrants (right to buy)
2.61
2023-07-13
4
P
0
83916
0.125
A
2023-07-14
2028-07-14
Common Stock
83916
83916
D
The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired $120,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 83,916 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant share) in accordance with Nasdaq rules.
/s/ Richard Wagner
2023-07-18